I-Mab Biopharma, a clinical stage biotech based in Shanghai with an exclusive focus on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and Jiangsu Nhwa Pharmaceutical (Nhwa), a company devoted to central nervous system (CNS) drug development, manufacturing and service, have entered into a collaborative research agreement with scientists and clinicians at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s ...